Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125174 · ClinicalTrials.gov registry record
Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 30
- Enrollment target
NCT03125174: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT03125174 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125174 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Analysis of mucus, mucin and DNA concentration, MUC5B/5AC ratio, rheology, osmotic pressure, cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy individuals and those with bronchiectasis. (60 total)
Primary Outcome
The percentage of solid content of sputum (an index of hydration) will be calculated my measuring the wet to dry weight ratio using a microbalance (mean percent solids ± standard deviation).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2017-06-27 |
What the finished NCT03125174 record still lists
NCT03125174 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03125174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03125174 about?
NCT03125174 is a clinical study titled "Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls". Analysis of mucus, mucin and DNA concentration, MUC5B/5AC ratio, rheology, osmotic pressure, cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy individuals and those with bronchiectasis. (60 total)
What is the current status of trial NCT03125174?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-03-10. Estimated completion is 2017-06-27.
Who is sponsoring clinical trial NCT03125174?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI